MoonLake Immunotherapeutics (MLTX) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Sector
Healthcare
Industry
Biotechnology
Employees
100
First IPO Date
October 20, 2020
| Name | Title | Pay | Year Born |
| Jorge Santos da Silva | Co-Founder, Interim Chair of the Board & CEO | 787,308 | 1977 |
| Matthias Bodenstedt | Chief Financial Officer | 626,532 | 1988 |
| Kristian Reich | Co-Founder & Chief Scientific Officer | 795,472 | 1966 |
| Nicolas Mosimann | General Counsel | 0 | N/A |
| Tino Anthamatten | Vice President of Marketing, Market Access & Pricing | 0 | N/A |
| Luciana Marques | Associate Vice-President of HR, People and Culture | 0 | N/A |
| Wulf Boecher | Chief Medical Officer | 0 | N/A |
| Oliver Daltrop | Chief Technical Officer | 0 | N/A |
| Carla Bretes | Director of Investor Relations & External Communications | 0 | N/A |
| Nuala Brennan | Chief Clinical Development Officer | 0 | N/A |
| Joana Cortez | Associate Vice-President of Legal & Compliance | 0 | N/A |
| Roman Akbar-Haase | Chief of Staff to the Executive Board | 0 | N/A |
MoonLake Immunotherapeutics operates as a clinical-stage biopharmaceutical company, concentrating its efforts on discovering and developing novel therapies. The company's primary focus is the advancement of Sonelokimab, an innovative, investigational Nanobody-based treatment engineered to target inflammatory conditions. Currently, Sonelokimab is undergoing mid-stage (Phase II) clinical trials for a range of inflammatory diseases, including hidradenitis suppurativa, psoriatic arthritis, and both ankylosing spondylitis and radiographic axial spondyloarthritis. Established in 2021, MoonLake Immunotherapeutics is based in Zug, Switzerland.